652 | EFFECTIVENESS AND SAFETY OF POLA‐R‐CHP REGIMEN IN PREVIOUSLY UNTREATED LOW‐RISK DLBCL: A NATIONWIDE MULTICENTER RETROSPECTIVE STUDY OF IPI 0–1 PATIENTS IN CHINA

Résumé fourni par la source

respectively, and the 12-month and 18-month OS rates were both 95.6% (Figure 2).In patients with extranodal involvement, the median number of involved organs was 2 (2-12).Patients' age > 60 years, IPI 3-5, Non-GCB, DEL, LDH > ULN, ECOG ≥ 2 points, and extranodal organ involvement >1 did not adversely impact on CRR, ORR, PFS, and OS in both univariate and multivariate analyses (p > 0.05).Conclusion: Our findings demonstrated that Pola-R-CHP achieves a high response rate among newly diagnosed DLBCL patients in real-world settings.Pola-R-CHP was shown to improve outcomes, even in patients with conventional high-risk factors.Additionally, patients exhibiting PR or SD during interim assessments were able to achieve a deeper response through continued Pola-R-CHP treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.